病例报告：一名受益于血液吸附治疗的新冠肺炎患者
Case Report: A Patient With COVID-19 Who Benefited From Hemoadsorption.
作者信息
Du Yinke, Qi Zhipeng, Ma Jiangwei, Sun Da, Yao Li, Xu Bin, Liu Wei, Xu Zhaofa, Deng Yu
机构信息
Department of Nephrology, First Hospital of China Medical University, Shenyang, China.
Department of Environmental Health, School of Public Health, China Medical University, Shenyang, China.
出版信息
Front Med (Lausanne). 2020 Dec 1;7:607849. doi: 10.3389/fmed.2020.607849. eCollection 2020.
In December 2019, the 2019 novel coronavirus disease (COVID-19), which has been identified to be caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China and spread across the world. Higher plasma levels of cytokines, including interleukin (IL)-6, IL-2, IL-7, IL-10, and tumor necrosis factor-α, were found in patients with COVID-19, which implies the occurrence of a cytokine storm and its association with disease severity. Extracorporeal blood purification has been proven to effectively remove the released inflammatory cytokines. In this study, we report on a patient with COVID-19 who benefited from hemoadsorption.
2019年12月，已确定由严重急性呼吸综合征冠状病毒2（SARS-CoV-2）引起的2019新型冠状病毒病（COVID-19）在中国出现并蔓延至全球。在COVID-19患者中发现其血浆中细胞因子水平升高，包括白细胞介素（IL）-6、IL-2、IL-7、IL-10和肿瘤坏死因子-α，这意味着细胞因子风暴的发生及其与疾病严重程度的关联。体外血液净化已被证明可有效清除释放的炎症细胞因子。在本研究中，我们报告了一名受益于血液吸附的COVID-19患者。
Zotero 插件